ACADIA Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript
Hi, everyone. Thanks for joining us at the Cowen Healthcare Conference. A fireside chat with ACADIA Pharmaceuticals. I'm covering analyst Ritu Baral. And with us from ACADIA, we have CEO, Steve Davis; CFO, Elena Ridloff; and President, Serge Stankovic. Thanks, everyone, Steve. Thank you. I will let you, Steve kick it off with just a couple of minutes of level setting where you guys are right now before we dive into questions.
That sounds great. Thanks much, Ritu. I'd like to start just with a few highlights, again, as you say, to level set.
First, we're driving NUPLAZID growth in PDP. In 2020, we achieved net sales of $441.8 million, representing 30% year-over-year growth. We continue to add new prescribers and new patients and see high adherence among our continuing PDP patients. Based on our 2020 performance and current outlook, we expect 2021 net sales in PDP, again, I just want
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |